Recruiting Clinical Trials

Reduced Immunogenicity Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma

By April 24, 2017 No Comments

Condition

Mesothelioma

Estimated Enrollment: 30

Age Group: 18 Years to 100 Years   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Primary Purpose: Treatment

Study ID Numbers: 160127|16-C-0127

Study First Received: June 10, 2016

Last Updated: April 20, 2017

Estimated Primary Completion Date: August 6, 2018

 

Primary Outcome Measures:

maximum tolerated dose|proportion of patients at MTD with paartial or complete response per RECIST|average time from treatment initiaition to disease progression or death|average time from start of treatment to death|pharmacokenetic characteristics|number of cycles LMB-100 can be given before ADAs develop|listing and frequency of treatment related adverse events

Sponsors and Collaborators:

National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)

Website Link: https://ClinicalTrials.gov/show/NCT02798536

Leave a Reply

Call Now ButtonCall Now